Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
The partnership aims to co-develop full-stack AI infrastructure, targeting enterprise and industrial use cases in Japan and beyond.
The ISM Services PMI unexpectedly fell to the breakeven point of 50, missing market forecasts and raising new questions about US economic momentum.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.